ARX Stock Overview
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARX from our risk checks.
Aroa Biosurgery Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.52 |
| 52 Week High | AU$1.10 |
| 52 Week Low | AU$0.49 |
| Beta | 0.68 |
| 1 Month Change | 2.97% |
| 3 Month Change | -29.73% |
| 1 Year Change | -48.51% |
| 3 Year Change | -55.56% |
| 5 Year Change | n/a |
| Change since IPO | -61.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -8.0% | -3.8% | -3.1% |
| 1Y | -48.5% | -8.7% | 4.0% |
Return vs Industry: ARX underperformed the Australian Biotechs industry which returned -8.7% over the past year.
Return vs Market: ARX underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ARX's share price has been volatile over the past 3 months.
Volatility Over Time: ARX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroabio.com |
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Aroa Biosurgery Limited Fundamentals Summary
| ARX fundamental statistics | |
|---|---|
| Market cap | AU$178.99m |
| Earnings (TTM) | -AU$7.61m |
| Revenue (TTM) | AU$60.51m |
2.9x
P/S Ratio-23.1x
P/E RatioIs ARX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARX income statement (TTM) | |
|---|---|
| Revenue | NZ$65.89m |
| Cost of Revenue | NZ$10.23m |
| Gross Profit | NZ$55.66m |
| Other Expenses | NZ$63.95m |
| Earnings | -NZ$8.29m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 84.47% |
| Net Profit Margin | -12.58% |
| Debt/Equity Ratio | 0% |
How did ARX perform over the long term?
See historical performance and comparison